New York, January 5, 2026, 14:21 EST — Regular session
- Viking Therapeutics shares were down about 10% as obesity-drug names swung on Novo’s U.S. Wegovy pill rollout.
- Novo said it set starter doses at $149 a month for cash-pay patients, with higher doses at $299.
- Investors’ next checkpoints include Viking’s Phase 3 enrollment milestones in Q1 and an earnings update expected Feb. 4 after the close (estimated).
Shares of Viking Therapeutics (VKTX) slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.
The move highlights how sensitive obesity-drug developers remain to pricing signals from the market leaders. Viking has no approved products, so changes in expected pricing can hit the stock as hard as trial data.
Direct-to-consumer discounts are also changing how investors think about margins and market share in a category once dominated by high list prices and insurance friction. For smaller developers, it tightens the trade-off between efficacy, side effects and cost.
Novo said it began selling once-daily Wegovy tablets in the United States on Monday, pricing the 1.5-milligram and 4-milligram starter doses at $149 a month for patients paying out of pocket. The Danish drugmaker set the 9 mg and 25 mg doses at $299 a month, said the 4 mg price will rise to $199 from April 15 and outlined distribution through major pharmacies and telehealth providers; under a deal with U.S. President Donald Trump, it and Eli Lilly agreed to offer starter doses at $149 a month through a TrumpRx site expected to launch this month. Lilly expects a decision in March on its own weight-loss pill and has said it would cap higher doses at $399 a month for repeat cash buyers.
Viking is developing VK2735, a dual GLP-1/GIP agonist — meaning it targets two hormones involved in appetite and glucose control — in both injectable and oral forms. The company said in November it completed enrollment in its VANQUISH-1 Phase 3 obesity trial and expected to finish enrollment for a second late-stage study in the first quarter of 2026.
Novo framed the rollout as a convenience play as well as a price move. “For many of them, that wait is over,” said Ed Cinca, a senior vice president at Novo Nordisk, in a release that also said the pill will be available through more than 70,000 U.S. pharmacies. PR Newswire
Viking has not issued a new press release since late November, leaving investors to trade the shares on sector headlines and any read-through for pricing and market share. That can amplify swings on days when the leaders reset expectations.
But the price fight raises the bar for newcomers. If payers and patients anchor on lower monthly costs, clinical upstarts may need clearer differentiation — or a partner with scale — to justify premium valuations.
